CBL-514 Enters Phase 3 Trials After Phase 2 Data Shows 12% Visceral Fat Reduction
CBL-514, a new injectable weight-loss drug, has entered Phase 3 clinical trials after Phase 2 results demonstrated significant reductions in visceral and subcutaneous fat. Unlike GLP-1 agonists that suppress appetite, CBL-514 induces apoptosis in fat cells, potentially offering a more permanent solution to weight regain. Early data shows a 12% drop in visceral fat within four weeks, with effects persisting after treatment cessation.
Key points
- CBL-514 is an injectable drug developed by Caliway Biopharmaceuticals that targets fat cells directly by blocking survival signals, causing them to die off.
- Phase 2 trials involving 40-41 participants showed a 12% reduction in visceral fat volume at week 4 and a 10.45% reduction at weeks 8-12 compared to baseline.
- The drug targets both subcutaneous fat (below the skin) and visceral fat (around organs), addressing metabolic risks like diabetes and heart disease.
- Unlike GLP-1 drugs, which often lead to weight regain after discontinuation, CBL-514 aims to reduce the capacity for fat reaccumulation by destroying fat cells.
- The drug is now entering Phase 3 trials, with the first trial recruiting participants and results expected by the end of 2027.
Background
This development follows ongoing concerns about GLP-1 weight-loss drugs, such as Ozempic and Wegovy, which can cause lean-mass loss and significant weight regain after stopping treatment. Recent studies have also linked GLP-1s to rare conditions like Wernicke encephalopathy. CBL-514 represents a shift toward therapies that physically reduce fat cell numbers rather than just suppressing appetite.
How outlets are covering it
The New York Post emphasizes the cosmetic benefits of CBL-514, such as a 'flatter stomach,' while highlighting its potential to address visceral fat. Medscape focuses on the clinical data, noting a 102 mL difference in visceral fat volume between CBL-514 and placebo groups at week 4. DongA Science stresses the drug's potential to prevent weight regain by limiting fat cell regrowth. PressReader mirrors the New York Post's focus on the drug's mechanism and its comparison to surgical alternatives like liposuction. All sources agree on the efficacy of CBL-514 in reducing fat, but differ in emphasis: some highlight cosmetic outcomes, while others focus on metabolic health and long-term weight stability.
Why it matters
CBL-514 could offer a more sustainable solution to obesity by targeting the root cause of fat accumulation rather than just appetite. Its ability to reduce visceral fat, which is linked to serious health conditions, could improve patient outcomes and reduce the burden of obesity-related diseases. The drug's progression to Phase 3 trials signals growing interest in non-GLP-1 approaches to weight management.
What to watch
CBL-514 is currently in Phase 3 clinical trials, with the first trial recruiting participants. Results are expected by the end of 2027. Researchers are also exploring whether CBL-514 can be combined with GLP-1 drugs to enhance weight loss and reduce the risk of weight regain after discontinuation.
- New weight-loss drug could give you a ‘flatter stomach’ in mere weeks — and unlike Ozempic, it targets belly fat directly New York Post
- New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells Medical Xpress
- Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial Medscape
- Next-generation obesity drug CBL-514 enters phase 3, destroying fat cells without rebound dongascience.com
- Rx LAYS ‘WAIST’ TO FAT PressReader
Want the full story? Read the original reporting
Read on New York Post